An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

Active, not recruitingOBSERVATIONAL

Enrollment

150,000

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Interventions

DRUG

Finerenone (Kerendia, BAY948862)

Follow clinical practice/administration.

DRUG

Others except finerenone

Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.

Trial Locations (1)

Bayer, Whippany